Merck: 4-week Hepatitis C treatment too short

CNBC's Meg Tirrell interviews Merck's Eliav Barr about the company's hepatitis C drug combination, which is aimed to shorten treatment time to four weeks. Analysts had warned success in the study could be a threat to Gilead, but the data missed expectations.